Hi Aamir -
From what you have said so far, it looks like your biomarker test results are:
- MSI status = "MSS (microsatellite stable)" i.e., not
- KRAS/NRAS status = "KRAS wild-type" i.e., not
Is that correct?
Your current stage seems to be:
Stage = "Stage 3b , mCRC recurrent with mets to peritoneum"
Is that correct?
In the United States, treatment standards are outlined in the NCCN Rectal Cancer guidelines. You can read the relevant sections there to get an idea what they recommend as treatment for mets to peritoneum.
The 2017 NCCN guideines for Rectal Cancer are contained in this 154-page document:https://www2.tri-kobe.org/nccn/guideline/colorectal/english/rectal.pdf
The discussion on peritoneal mets is found in section MS-31 and starts on page 76 of the document. It covers the topics of:Peritoneal Carcinogenesis
andCytoreductive Debulking (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC)
The discussion of chemotherapy treatment plans is found in section MS-36 and starts on page 81 of the document.
aam7.00 wrote:" 5FU+ oxaliplatin+ Bevacizumab and other one says, capecitabine+ Oxaliplatin+cetuximab"
Please note that the 2 regimens you mentioned above are known by several different names, including:
- = FOLFOX+Avastin(bevacizumab)
- = XELOX+Erbitux (cetuximab) = CAPEOX+Erbitux (cetuximab)
You can look through section MS-36 above to see what they say about these regimens.
- - - -
There is another resource that you could consult. It is the MD Anderson decision tree for deciding optimal therapy regimens under various scenarios:https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/cancer-treatment/ca-treatment-colon-web-algorithm.pdf